• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

    2/13/24 5:13:53 PM ET
    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PKI alert in real time by email
    SC 13G/A 1 tv01821-revvityinc.htm SCHEDULE 13G/A revvityinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 15)*

    Name of issuer:  Revvity Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  714046109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  714046109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    150,526

    7.  SOLE DISPOSITIVE POWER

    13,656,528

    8.  SHARED DISPOSITIVE POWER

    520,575

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,177,103

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.49%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Revvity Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    940 Winter Street
    Waltham, MA 02451

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    714046109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $PKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PKI

    DatePrice TargetRatingAnalyst
    12/19/2022$170.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2022$135.00 → $170.00Neutral → Buy
    Citigroup
    12/6/2022$192.00 → $164.00Market Perform → Outperform
    Cowen
    11/28/2022$130.00 → $145.00Underweight → Equal Weight
    Barclays
    8/25/2022$175.00Neutral
    Credit Suisse
    8/18/2022$190.00 → $170.00Buy → Hold
    Stifel
    8/2/2022$178.00Buy → Neutral
    BofA Securities
    7/20/2022$160.00Buy
    UBS
    More analyst ratings

    $PKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PerkinElmer upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded PerkinElmer from Sector Weight to Overweight and set a new price target of $170.00

      12/19/22 7:48:08 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Citigroup with a new price target

      Citigroup upgraded PerkinElmer from Neutral to Buy and set a new price target of $170.00 from $135.00 previously

      12/12/22 7:52:36 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Cowen with a new price target

      Cowen upgraded PerkinElmer from Market Perform to Outperform and set a new price target of $164.00 from $192.00 previously

      12/6/22 7:47:47 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Ares Management Corporation Announces U.S. Direct Lending Origination Activity for the First Quarter and Last Twelve Months 2023

      Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun

      4/28/23 6:30:00 AM ET
      $ARES
      $PKI
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    SEC Filings

    See more
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      2/1/24 6:05:15 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Leadership Update

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/26/24 8:00:33 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/9/24 8:05:29 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Board Declares Quarterly Dividend

      The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon

      4/25/23 4:05:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 4:11:39 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 10:04:34 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/13/24 5:13:53 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:33:35 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:09:03 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Klobuchar Michael A was granted 481 shares (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 4:05:16 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Leadership Updates

    Live Leadership Updates

    See more
    • James Mock Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a

      8/17/22 8:00:00 AM ET
      $MRNA
      $PKI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Announces Finance Leadership Transition

      Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey

      8/17/22 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

       Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a

      4/13/21 4:15:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials